Introduction
The free-hormone hypothesis assumes that the concentration of circulating hormone that is available for uptake by tissues in vivo is equal to the concentration of free hormone measured in vitro, e.g., by equilibrium dialysis (1, 2) . Similar precepts hold for the free-drug hypothesis (3) . Implicit in these formulations is the assumption that the binding constants that govern the ligand-plasma protein interactions in vivo in the microenvironment of the tissue capillary are approximated by the binding constants observed in vitro. Previous studies from our laboratory since 1979 have reported the effects of plasma proteins on the blood-brain barrier (BBB)' transport of steroid hormones (4), thyroid hormones (5, 6) , free fatty acids (7) , and drugs (8) . These studies have shown that the apparent dissociation constant, KDa, of plasma protein-binding of ligands in vivo in the brain capillary is in most cases many times greater than the in vitro dissociation constant, KD. That is, the dissociation of ligands from plasma proteins is enhanced in the micro-environment of the living capillary such that the concentration of available (transportable) hormone in vivo is many times greater than the concentration of free hormone in vitro. On the basis of these observations we have suggested that the precepts of the free-hormone hypothesis are false (9) . However, Robbins and Johnson (10) and Ekins et al. (11) have recently attempted to reconcile the free hormone hypothesis with our experimental observations. Such a reconciliation would probably require unphysiologically high membrane permeability constants, since we have observed that tissues rapidly take up hormone from the circulation in excess of the freehormone pool in plasma. The conflicting interpretations of the relevance of our data to the free-hormone hypothesis may be attributed to the lack of a mathematical model that allows 1. Abbreviations used in this paper: AF, plasma protein concentration; BBB, blood-brain barrier; E, unidirectional ligand extraction; KD, for the quantitative analysis of the transport of free and bound hormones in vivo. Therefore, the purpose of the present studies was to elaborate a tracer-kinetic model and to fit the experimental data to the model given the assumptions of the opposing hypotheses. In the first case (9) (e.g., case I) it is assumed that the rate of ligand dissociation from plasma protein in vivo may be enhanced relative to the in vitro situation, and in the second case (10, 11) (e.g., case II) it is assumed that the dissociation rate in vivo is fixed at the in vitro value.
Methods
Carotid artery injection technique. The measurement of E, the unidirectional extraction, for the six ligands under study, (estradiol, testosterone, dihydrotestosterone, corticosterone, triiodothyronine [T3], and propranolol) has been reported previously (4, 5, 8) (13, 14) . With regard to the test compounds, the extraction at 15 s is not significantly different from the initial extraction. Owing to active sequestration mechanisms in the brain for the steroid hormones and for propranolol, the half-life of ligand distribution in brain after a pulse injection is 4-6 min (14, 15) . Therefore, the ligand efflux to blood in 15 s is <5%. In addition, previous studies have shown that the amount of recirculating test or reference isotope is not quantitatively significant relative to the amount of radioactivity in brain for up to 4 min after injection (14 There are two approaches by which Eq. I may be fitted to the ligand extraction-plasma protein curves. In case I, two parameters, i.e., the k3T product and the KD, are estimated by nonlinear regression analysis. In this approach, the in vivo KDa is determined from the analysis of the in vivo transport data, which allow for estimation of the apparent dissociation constant in the milieu of the brain capillary. In case II, the KD' is fixed at the absolute KD value as measured in vitro by equilibrium dialysis, and only one parameter, the k3t product, is estimated from nonlinear regression analysis. The fundamental assumption made in the case II analyses is that the protein-ligand dissociation constant in a living capillary is identical to the absolute KD measured in a test tube, e.g., by equilibrium dialysis. The absolute KD values for albumin binding of corticosterone, dihydrotestosterone, testosterone, estradiol, T3, and propranolol, and for orosomucoid binding of propranolol are listed in Table I . The absolute KD values are determined by equilibrium dialysis at 370C (4, 5, 8) .
The fitting of Eq. I to extraction-plasma protein concentration curves is performed with an unweighted least squares regression analysis (subroutine PAR, BMDP programs 119]) for both the twoparameter (case I) and one-parameter (case II) studies. The k3t product estimated by either the case I or case II analyses is compared with the k3t product determined with the Kety-Renkin-Crone relationship (Eq. 2) and the ligand extraction at zero protein concentration. Alternate weighted least squares estimates were made with weights equal to the reciprocal ofthe squared standard errors of the observations. The results were similar, and only unweighted least squares estimate are reported. Since case II is a restriction of case I with one less Figure 1 (Fig. 6 ). Both approaches give identical estimates of k3t, and the in vivo KDa estimated by the case I analysis is not significantly different from the in vitro KD (case II, Fig. 6 ). The data in Fig. 6 in these studies can in one case achieve confirming estimates of the KD as measured either in vivo in brain capillaries or in vitro by equilibrium dialysis.
Discussion
The present studies constitute a quantitative analysis of previously reported data within the context of a mathematical model ( Fig. 1) (Fig. 1) . Second, it is assumed that the ligandprotein binding reaction remains at near-equilibrium during the course of bolus passage through the brain. Third, no dilution artifacts are caused by a mixing of the injection bolus with the circulating rat plasma. Fourth, ligand-protein interactions are linear or first order. Fifth, membrane transport of free ligand is first order at the concentration of labeled ligand used in these studies. Sixth, the brain microcirculation is endowed with a specific mechanism that leads to enhanced dissociation of the ligand from the protein, such that proteinbound hormone is available for transport through the membrane, while the plasma protein remains in the capillary plasma space.
The use of the compartmental model in Fig. I A bolus injection technique may be used quantitatively to assess in vivo plasma protein binding if the binding reaction between ligand and plasma protein is in near-equilibrium during the course of the bolus transit through the capillary (21). This assumption requires that binding reactions are fast relative to the transport reaction, i.e., k2AF and/or k, > k3 and k4 (see Appendix). Because k3F products range from 0.14 to 2.6 and (is approximately equal to 1 s, k3 ranges from 0.14 to 2.6. Since AF = 10-1,500 MM (Figs. 2-7) , it is assumed that k2 0> I0-104 M-s-l. The minimum value for hormoneplasma protein association reactions is 106_108 M-l s-' (24) . Therefore, the assumption of near-equilibrium for the binding reaction appears justified (4) .
The assumption that there is insignificant mixing of the bolus with the circulating rat plasma may be attributed to the fact that the rate of carotid injection (>0.3 ml/s or >18 ml/ min) exceeds the rate of common carotid blood flow (5 ml/ min) in the barbiturate-anesthetized rat (25) . The bolus nature of the passage of the injection solution through brain is supported by the observation that 96% of the injection solution has already cleared the brain by 2 s after injection (12) . The maintenance of a bolus for at least one circulation is also shown in the early studies of Paton (see Fig. 1 of reference  26 ). In addition, from our previous studies of BBB transport of glucose and amino acids, there is direct experimental support for the assumption of insignificant bolus mixing. For example, the inclusion of 90% serum in the carotid artery injection solution results in 85% inhibition of the extraction of arginine, an amino acid that is transported through the BBB by a specific transport system that is heavily saturated by normal plasma amino acid concentrations (27, 28 The assumptions about linearity ofthe binding and transport reactions appear reasonable since (a) the concentration of tracer hormone or drug used in these studies is <0.1 M, which is small compared with the minimum KD of the binding proteins used (Table I) , and (b) membrane transport is nonsaturable for all the ligands studied when ligand concentration is <0.1 MAM (4, 5, 6, 15) .
Given the' validity of the above assumptions, we conclude that ligand binding to plasma proteins is, in most cases, altered in the microcirculation so that-the system operationally behaves as if the dissociation constant of the binding reaction is greatly increased relative to the in vitro situation. One possible mechanism by which this might happen is the release from the endothelial surface of noncompetitive plasma protein-binding inhibitors. The putative inhibitor might be free fatty acids, since Chopra et al. (29) (Fig. 6) . Similarly, albuminbound phenobarbital is not available for transport through the adult rat BBB (30) .
Another possible mechanism by which albumin-bound ligands may be transported into tissues is a receptor-mediated process. Weisiger et al. (31) and Forker and Luxon (32) propose that albumin binds to a hepatocyte surface receptor that has a relatively high affinity for albumin, e.g., a dissociation constant of 25-50 ,uM albumin. The evidence for the receptor hypothesis is, in part, the observed decrease in the rate of transport of protein-bound ligand caused by increasing concentrations ofalbumin (31, 32) . We observe this same saturation phenomenon (Figs. 2-7) . However, we find that the extent to which the transport of albumin-bound ligands is saturated by the plasma protein is quite variable from ligand to ligand (Table I) . If albumin-bound ligands are transported through the BBB via a single endothelial albumin receptor, it would be expected that the saturation of the process by albumin is comparable for all albumin-bound ligands. With regard to BBB transport of protein-bound ligands, it is not possible at present to discriminate between an inhibitor model and a receptor model. Both of these possible mechanisms are the subject of our present laboratory investigation.
Appendix
Mathematical model. These studies employ a compartmental model depicting the transport of a protein-bound ligand through the BBB and into the brain (Fig. 1) . If a relatively fixed concentration of free protein is assumed, the differential equations of the model are The equations that define LM(t), LF(t), and AL(t) may be simplified to approximate solutions if specific restrictions on the rate constants are applied. If it is assumed that k2AF and/or k, > k3 and k4, then the system of equations becomes relatively stiff such that the ligand-protein dynamics is much faster than the transport kinetics. Therefore, in the transport time scale, Eq. 3 is in approximate equilibrium, and AL(t Letting the extraction of the ligand by the tissue be defined by E(t) = LTV VT (8) and integrating Eq. 7, with LM(O) = 0, gives (9) E I[ + k4(I +1AF/KDa)/kj{ 1 -Eq. 9 may be further simplified if it is assumed that k4(1 + AF/KD) << k3 (footnote 3).
Therefore, if the time variable is set equal to the mean transit time, t, Eq. 9 reduces to Eq. I of the text E = I -ek3t/(+F/K)
